The application of the Open Pharmacological Concepts Triple Store (Open PHACTS) to support drug discovery research

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Ratnam, Joseline ^a   Zdrazil, Barbara ^b   Digles, Daniela ^b   Cuadrado Rodriguez, Emiliano ^a   Neefs, Jean Marc ^c   Tipney, Hannah ^e   Siebes, Ronald ^f   Waagmeester, Andra ^g   Bradley, Glyn ^e   Chau, Chau Han ^e   Richter, Lars ^b   Brea, Jose ^a   Evelo, Chris T ^g   Jacoby, Edgar ^c   Senger, Stefan ^e   Loza, Maria Isabel ^a   Ecker, Gerhard F ^b   Chichester, Christine ^d  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b UNIVERSITY OF VIENNA   (Austria)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^d SWISS INSTITUTE OF BIOINFORMATICS   (Switzerland)

^e GLAXOSMITHKLINE   (United Kingdom)

^f VU UNIVERSITY AMSTERDAM   (Netherlands)

^g MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE 2 RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; VITAMIN D RECEPTOR;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG DATABASE; DRUG DESIGN; DRUG IDENTIFICATION; DRUG PROGRAM; DRUG RESEARCH; DRUG TARGETING; KNOWLEDGE MANAGEMENT; SIGNAL TRANSDUCTION; VITAMIN D METABOLISM; WORKFLOW; COMPUTER PROGRAM; DATA BASE; DRUG DEVELOPMENT; ORGANIZATION AND MANAGEMENT; PROCEDURES; STATISTICS AND NUMERICAL DATA;

DATABASES AS TOPIC; DRUG DISCOVERY; SOFTWARE;

EID: 84919372736     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0115460     Document Type: Article

References (68)

1. Lanfear J (2002) Dealing with the data deluge. Nat Rev Drug Discov 1: 479.
2. Samwald M, Jentzsch A, Bouton C, Kallesoe CS, Willighagen E, et al. (2011) Linked open drug data for pharmaceutical research and development. J Cheminform 3: 19-2946-3-19.
3. Keiser MJ, Setola V, Irwin JJ, Laggner C, Abbas AI, et al. (2009) Predicting new molecular targets for known drugs. Nature 462: 175-181.
4. Bender A, Young DW, Jenkins JL, Serrano M, Mikhailov D, et al. (2007) Chemogenomic data analysis: Prediction of small-molecule targets and the advent of biological fingerprint. Comb Chem High Throughput Screen 10: 719-731.
5. Gregori-Puigjane E, Setola V, Hert J, Crews BA, Irwin JJ, et al. (2012) Identifying mechanism-ofaction targets for drugs and probes. Proc Natl Acad Sci U S A 109: 11178-11183.
6. Williams AJ, Harland L, Groth P, Pettifer S, Chichester C, et al. (2012) Open PHACTS: Semantic interoperability for drug discovery. Drug Discov Today 17: 1188-1198.
7. Gray AJ, Groth P, Loizou A, Askjaer S, Brenninkmeijer C, et al. (2014) Applying Linked Data Approaches to Pharmacology: Architectural Decisions and Implementation. Semantic Web Journal 10.3233/SW-2012-0088
8. Belleau F, Nolin MA, Tourigny N, Rigault P, Morissette J (2008) Bio2RDF: Towards a mashup to build bioinformatics knowledge systems. J Biomed Inform 41: 706-716.
9. Chen B, Dong X, Jiao D, Wang H, Zhu Q, et al. (2010) Chem2Bio2RDF: A semantic framework for linking and data mining chemogenomic and systems chemical biology data. BMC Bioinformatics 11: 255-2105-11-255.
10. Hardy B, Douglas N, Helma C, Rautenberg M, Jeliazkova N, et al. (2010) Collaborative development of predictive toxicology applications. J Cheminform 2: 7-2946-2-7.
11. Azzaoui K, Jacoby E, Senger S, Rodriguez EC, Loza M, et al. (2013) Scientific competency questions as the basis for semantically enriched open pharmacological space development. Drug Discov Today 18: 843-852.
12. Kelder T, van Iersel MP, Hanspers K, Kutmon M, Conklin BR, et al. (2012) WikiPathways: Building research communities on biological pathways. Nucleic Acids Res 40: D1301-7.
13. Berthold M, Cebron N, Dill F, Gabriel T, Kötter T, et al. (2008) KNIME: The konstanz information miner. In: Preisach C, Burkhardt H, Schmidt-Thieme L, Decker R, editors.: Springer Berlin Heidelberg. pp.319-326.
14. Accelrys (2010) Pipeline pilot. Availble: http://accelrys.com/products/pipeline-pilot/. Accessed 2014 Nov 30.
15. Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, et al. (2012) ChEMBL: A large-scale bioactivity database for drug discovery. Nucleic Acids Res 40: D1100-7.
16. Bento AP, Gaulton A, Hersey A, Bellis LJ, Chambers J, et al. (2014) The ChEMBL bioactivity database: An update. Nucleic Acids Res 42: D1083-90.
17. Degtyarenko K, de Matos P, Ennis M, Hastings J, Zbinden M, et al. (2008) ChEBI: A database and ontology for chemical entities of biological interest. Nucleic Acids Res 36: D344-50.
18. de Matos P, Alcantara R, Dekker A, Ennis M, Hastings J, et al. (2010) Chemical entities of biological interest: An update. Nucleic Acids Res 38: D249-54.
19. Hastings J, de Matos P, Dekker A, Ennis M, Harsha B, et al. (2013) The ChEBI reference database and ontology for biologically relevant chemistry: Enhancements for 2013. Nucleic Acids Res 41: D456-63.
20. Knox C, Law V, Jewison T, Liu P, Ly S, et al. (2011) DrugBank 3.0: A comprehensive resource for 'omics' research on drugs. Nucleic Acids Res 39: D1035-41.
21. Williams AJ, Tkachenko V, Golotvin S, Kidd R, McCann G (2010) ChemSpider - building a foundation for the semantic web by hosting a crowd sourced databasing platform for chemistry. Journal of Cheminformatics 2: O16-O16. doi: 10.1186/1758-2946-2-s1-o16
22. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, et al. (2000) Gene ontology: Tool for the unification of biology. the gene ontology consortium. Nat Genet 25: 25-29.
23. Hill DP, Smith B, McAndrews-Hill MS, Blake JA (2008) Gene ontology annotations: What they mean and where they come from. BMC Bioinformatics 9 Suppl 5:: S2-2105-9-S5-S2.
24. Apweiler R, Bairoch A, Wu CH, Barker WC, Boeckmann B, et al. (2004) UniProt: The universal protein knowledgebase. Nucleic Acids Res 32: D115-9.
25. Bairoch A (2000) The ENZYME database in 2000. Nucleic Acids Res 28: 304-305.
26. Chichester C, Mons B (2011) Collaboration and the Semantic Web. In: Collaborative Computational Technologies for Biomedical Research. Ekins S, Hupcey MAZ, Williams AJ editors. John Wiley & Sons, Inc. New Jersey. pp453-465
27. Altschul SF, Madden TL, Schäffer AA, Zhang J, Zhang Z, et al. (1997) Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 25: 3389-3402.
28. Berridge KC (2007) The debate over dopamine's role in reward: The case for incentive salience. Psychopharmacology (Berl) 191: 391-431.
29. Beaulieu JM, Gainetdinov RR (2011) The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev 63: 182-217.
30. Sibley DR, Monsma FJ Jr (1992) Molecular biology of dopamine receptors. Trends Pharmacol Sci 13: 61-69.
31. Civelli O, Bunzow JR, Grandy DK (1993) Molecular diversity of the dopamine receptors. Annu Rev Pharmacol Toxicol 33: 281-307.
32. Seeman P (2010) Dopamine D2 receptors as treatment targets in schizophrenia. Clin Schizophr Relat Psychoses 4: 56-73.
33. Hynes NE, Lane HA (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5: 341-354
34. Gondi CS, Dinh DH, Klopfenstein JD, Gujrati M, Rao JS (2009) MMP-2 downregulation mediates differential regulation of cell death via ErbB-2 in glioma xenografts. Int J Oncol 35: 257-263.
35. Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signaling network. Nat Rev Mol Cell Biol 2: 127-137.
36. Yarden Y, Pines G (2012) The ERBB network: at last, cancer therapy meets systems biology. Nat Rev Cancer 12: 553-563.
37. Olsen JV, Blagoev B, Gnad F, Macek B, Kumar C, et al. (2006) Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Cell 127: 635-648.
38. Ridolfi E, Barone C, Scarpini E, Galimberti D (2013) The role of the innate immune system in Alzheimer's disease and frontotemporal lobar degeneration: an eye on microglia. Clin Dev Immunol 2013: 939786.
39. Blach-Olszewska Z, Leszek J (2007) Mechanisms of over-activated innate immune system regulation in autoimmune and neurodegenerative disorders. Neuropsychiatr Dis Treat 3: 365-372.
40. Holick MF, Schnoes HK, DeLuca HF (1971) Identification of 1,25-dihydroxycholecalciferol, a form of vitamin D3 metabolically active in the intestine. Proc Natl Acad Sci U S A 68: 803-804.
41. Fleet JC (2006) Molecular regulation of calcium and bone metabolism through the vitamin D receptor. J Musculoskelet Neuronal Interact 6: 336-337.
42. Haussler MR, Whitfield GK, Haussler CA, Hsieh JC, Thompson PD, et al. (1998) The nuclear vitamin D receptor: Biological and molecular regulatory properties revealed. J Bone Miner Res 13: 325-349.
43. Deluca HF, Cantorna MT (2001) Vitamin D: Its role and uses in immunology. FASEB J 15: 2579-2585.
44. Mathieu C, Adorini L (2002) The coming of age of 1,25-dihydroxyvitamin D(3) analogs as immunomodulatory agents. Trends Mol Med 8: 174-179.
45. van Etten E, Mathieu C (2005) Immunoregulation by 1,25-dihydroxyvitamin D3: Basic concepts. J Steroid Biochem Mol Biol 97: 93-101.
46. Baeke F, Etten EV, Overbergh L, Mathieu C (2007) Vitamin D3 and the immune system: Maintaining the balance in health and disease. Nutr Res Rev 20: 106-118.
47. Brown AJ, Slatopolsky E (2008) Vitamin D analogs: Therapeutic applications and mechanisms for selectivity. Mol Aspects Med 29: 433-452.
48. Fleet JC (2008) Molecular actions of vitamin D contributing to cancer prevention. Mol Aspects Med 29: 388-396.
49. Kedjouar B, de Medina P, Oulad-Abdelghani M, Payre B, Silvente-Poirot S, et al. (2004) Molecular characterization of the microsomal tamoxifen binding site. J Biol Chem 279: 34048-34061.
50. Jones G, Prosser DE, Kaufmann M (2012) 25-hydroxyvitamin D-24-hydroxylase (CYP24A1): Its important role in the degradation of vitamin D. Arch Biochem Biophys 523: 9-18.
51. Gomme PT, Bertolini J (2004) Therapeutic potential of vitamin D-binding protein. Trends Biotechnol 22: 340-345.
52. Prosser DE, Jones G (2004) Enzymes involved in the activation and inactivation of vitamin D. Trends Biochem Sci 29: 664-673.
53. Luo W, Hershberger PA, Trump DL, Johnson CS (2013) 24-hydroxylase in cancer: Impact on vitamin D-based anticancer therapeutics. J Steroid Biochem Mol Biol 136: 252-257.
54. Saito N, Suhara Y, Abe D, Kusudo T, Ohta M, et al. (2009) Synthesis of 2alpha-propoxy-1alpha,25-dihydroxyvitamin D3 and comparison of its metabolism by human CYP24A1 and rat CYP24A1. Bioorg Med Chem 17: 4296-4301.
55. Zhou X, Zhu GD, Van Haver D, Vandewalle M, De Clercq PJ, et al. (1999) Synthesis, biological activity, and conformational analysis of four seco-D-15,19-bisnor-1alpha,25-dihydroxyvitamin D analogues, diastereomeric at C17 and C20. J Med Chem 42: 3539-3556.
56. Boehm MF, Fitzgerald P, Zou A, Elgort MG, Bischoff ED, et al. (1999) Novel nonsecosteroidal vitamin D mimics exert VDR-modulating activities with less calcium mobilization than 1,25-dihydroxyvitamin D3. Chem Biol 6: 265-275.
57. Swann SL, Bergh J, Farach-Carson MC, Ocasio CA, Koh JT (2002) Structure-based design of selective agonists for a rickets-associated mutant of the vitamin d receptor. J Am Chem Soc 124: 13795-13805.
58. Perakyla M, Malinen M, Herzig KH, Carlberg C (2005) Gene regulatory potential of nonsteroidal vitamin D receptor ligands. Mol Endocrinol 19: 2060-2073.
59. Ma Y, Khalifa B, Yee YK, Lu J, Memezawa A, et al. (2006) Identification and characterization of noncalcemic, tissue-selective, nonsecosteroidal vitamin D receptor modulators. J Clin Invest 116: 892-904.
60. Asano L, Ito I, Kuwabara N, Waku T, Yanagisawa J, et al. (2013) Structural basis for vitamin D receptor agonism by novel non-secosteroidal ligands. FEBS Lett 587: 957-963.
61. Bai X, Miao D, Goltzman D, Karaplis AC (2007) Early lethality in Hyp mice with targeted deletion of Pth gene Endocrinology, 148 (10). pp.4974-4983
62. Roy S, Martel J, Ma S, Tenenhouse HS (1994) Increased renal 25-hydroxyvitamin D3-24-hydroxylase messenger ribonucleic acid and immunoreactive protein in phosphate-deprived hyp mice: A mechanism for accelerated 1,25-dihydroxyvitamin D3 catabolism in X-linked hypophosphatemic rickets. Endocrinology 134: 1761-1767.
63. Anderson MG, Nakane M, Ruan X, Kroeger PE, Wu-Wong JR. (2006) Expression of VDR and CYP24A1 mRNA in human tumors. Cancer Chemother Pharmacol 57: 234-240.
64. Larriba MJ, Martin-Villar E, Garcia JM, Pereira F, Pena C, et al. (2009) SNAIL2 cooperates with SNAIL1 in the repression of vitamin D receptor in colon cancer. Carcinogenesis 30: 1459-1468.
65. Larriba MJ, Casado-Vela J, Pendas-Franco N, Pena R, Garcia de Herreros A, et al. (2010) Novel SNAIL1 target proteins in human colon cancer identified by proteomic analysis. PLoS One 5: e10221.
66. Palmer HG, Larriba MJ, Garcia JM, Ordonez-Moran P, Pena C, et al. (2004) The transcription factor SNAIL represses vitamin D receptor expression and responsiveness in human colon cancer. Nat Med 10: 917-919.
67. Larriba MJ, Bonilla F, Munoz A (2010) The transcription factors Snail1 and Snail2 repress vitamin D receptor during colon cancer progression. J Steroid Biochem Mol Biol 121: 106-109.
68. Loizou A, Angles R, Groth P (2014) On the Formulation of Performant SPARQL Queries. Submitted: Journal of Web Semantics, June 2014